Hemochromatosis subjects as allogeneic blood donors: A prospective study

Transfusion

Volumn 43, Issue 11, 2003, Pages 1538-1544

  Leitman, Susan F ^a   Browning, Janet N ^b   Yau, Yu Ying ^b   Mason, Glorice ^b   Klein, Harvey G ^b   Conry Cantilena, Cathy ^b   Bolan, Charles D ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFERRIN;

ADULT; AGED; ARTICLE; BLOOD DONOR; BLOOD TRANSFUSION; ERYTHROCYTE TRANSFUSION; FEMALE; GENE MUTATION; HEALTH CARE ACCESS; HEMOCHROMATOSIS; HEMOGLOBIN DETERMINATION; HOMOZYGOSITY; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PHLEBOTOMY; PROSPECTIVE STUDY; RISK ASSESSMENT; SAFETY;

ADULT; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; BLOOD DONORS; ERYTHROCYTE INDICES; HEMOCHROMATOSIS; HUMANS; LIVER; MIDDLE AGED; PHLEBOTOMY; PROSPECTIVE STUDIES;

EID: 0242440043     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.2003.00570.x     Document Type: Article

References (27)

1. Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996;13:399-408.
2. Bacon BR. Diagnosis and management of hemochromatosis. Gastroenterology 1997;113:995-9.
3. Olynyk JK, Cullen DJ, Aquilia S, et al. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 1999;341:718-24.
4. Brissot P, Moirand R, Jouanolle AM, et al. A genotypic study of 217 unrelated probands diagnosed as "genetic hemochromatosis" on "classical" phenotypic criteria. J Hepatol 1999; 30:588-93.
5. Roy CN, Enns CA. Iron homeostasis: new tales from the crypt. Blood 2000;96:4020-7.
6. Andrews NC. Medical progress: disorders iron metabolism. N Engl J Med 1999;341:1986-95.
7. Edwards CQ, Cartwright GE, Skolnick MH, Amos DB. Homozygosity for hemochromatosis: clinical manifestations. Ann Intern Med 1980;93:519-25.
8. Bothwell TH, MacPhail AP. Hereditary hemochromatosis. etiologic, pathologic, and clinical aspects. Semin Hematol 1998;35:55-71.
9. Beutler E, Felitti VJ, Koziol JA, et al. Penetrance of 845G→A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002;359:211-8.
10. Motulsky AG, Beutler E. Population screening in hereditary hemochromatosis. Annu Rev Pub Health 2000;21:65-79.
11. Crosby WH. A history of phlebotomy therapy for hemochromatosis. Am J Med Sci 1991;301:28-31.
12. Barton JC, McDonnell SM, Adams PC, et al. Management of hemochromatosis. Hemochromatosis Management Working Group. Ann Intern Med 1998;129:932-9.
13. Niederau C, Fischer R, Purschel A, et al. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996;110:1107-19.
14. Conry-Cantilena C, Klein HG. Hemochromatosis patients as blood and tissue donors. In: Barton JC, Edwards CQ, editors. Hemochromatosis: genetics, pathophysiology, diagnosis, and treatment. Cambridge: Cambridge University Press, 2002:555-63.
15. Guidance for industry: variances for blood collection from individuals with hereditary hemochromatosis. Rockville (MD): Center for Biologics Evaluation and Research; 2001 Aug (Accessed 2002 Aug 13). Available from: http://www.fda.gov/cber/gdlns/hemchrom.htm
16. Bolan CD, Conry-Cantilena C, Mason G, et al. MCV as a guide to phlebotomy therapy for hemochromatosis. Transfusion 2001;41:819-27.
17. Bolan CD, Yau YY, Mason G, et al. Controlled study of changes in iron parameters during MCV-guided phlebotomy therapy for hereditary hemochromatosis. Blood 2001;98:62a.
18. Shi PA, Ness PM. Two-unit red cell apheresis and its potential advantages over traditional whole-blood donation. Transfusion 1999;39:218-25.
19. Blacklock HA, Dewse M, Bollard C, et al. Blood donation by healthy individuals with haemochromatosis. N Z Med J 2000;113:77-8.
20. McDonnell SM, Preston BL, Jewell SA, et al. A survey of 2,851 patients with hemochromatosis: symptoms and response to treatment. Am J Med 1999;106:619-24.
21. Sanchez AM, Schreiber GB, Bethel J, et al. Prevalence, donation practices, and risk assessment of blood donors with hemochromatosis. JAMA 2001;286:1475-81.
22. Barton JC, Grindon AJ, Barton NH, Bertoli LF. Hemochromatosis probands as blood donors. Transfusion 1999;39:578-85.
23. Beutler E. The HFE Cys282Tyr mutation as a necessary but not sufficient cause of clinical hereditary hemochromatosis. Blood 2003;101:3347-50.
24. Ajioka RS, Kushner JP. Clinical consequences of iron overload in hemochromatosis homozygotes. Blood 2003;101: 3351-3.
25. Bulaj ZJ, Ajioka RS, Phillips JD, et al. Disease-related conditions in relatives of patients with hemochromatosis. N Engl J Med 2000;343:1529-35.
26. Beutler E. Rebuttal to Ajioka and Kushner. Blood 2003;101: 3354-7.
27. Voelker R. Hemochromatosis patients are untapped source of blood as war, shortages loom. JAMA 2003;289:1364-6.